Modality
Small Molecule
MOA
Menini
Target
FcRn
Pathway
Complement
ACCCRCMeso
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
→ Nov 2025
Phase 1Current
NCT06087467
1,574 pts·CRC
2022-09→2025-03·Active
NCT07571175
1,658 pts·CRC
2019-05→2025-11·Active
3,232 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-101.1y agoPh2 Data· CRC
2025-11-125mo agoPh2 Data· CRC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1/2
Active
P1/2
Active
Catalysts
Ph2 Data
2025-03-10 · 1.1y ago
CRC
Ph2 Data
2025-11-12 · 5mo ago
CRC
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06087467 | Phase 1/2 | CRC | Active | 1574 | EASI-75 |
| NCT07571175 | Phase 1/2 | CRC | Active | 1658 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |